All In Biotech

NDA 021489 · Bracco

Prohance Multipack

Gadoteridol · Injection · Paramagnetic Contrast Agent

Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Oct 9, 2003

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

4 Phase 3, 2 recruiting

FAERS reports

1,816

1,516 serious, 162 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. ProHance is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of ProHance in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR less than 30 mL/min/1.73m 2 ), or acute...

What it is approved for

From the label in effect Mar 14, 2025.

ProHance Multipack is a gadolinium-based contrast agent indicated for magnetic resonance imaging (MRI) to visualize: lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues in adults and pediatric patients, including term neonates ( 1.1 ) lesions in the head and neck in adults ( 1.2 ) 1.1 MRI of the Central Nervous System (CNS) ProHance is indicated for magnetic resonance imaging (MRI) in adults and pediatric patients including term neonates to visualize lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. 1.2 MRI of Extracranial/Extraspinal Tissues ProHance is indicated for MRI in adults to visualize lesions in the head and neck.

Mechanism: Gadoteridol is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent. In MRI, visualization of normal and pathologic brain tissue depends, in part, on variations in the radiofrequency signal intensity that occur with: 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3)...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROHANCE MULTIPACK · GADOTERIDOL 279.3MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadoteridol" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nephrogenic systemic fibrosis587
  • pain407
  • anxiety254
  • emotional distress223
  • mobility decreased186
  • general physical health deterioration184
  • fibrosis183
  • injury178
  • scar159
  • skin hypertrophy154
  • skin induration151
  • pruritus147

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200427
200528
200641
200742
200847
200970
2010176
2011208
201292
201350
2014121
201533
201664
201778
201885
201993
202085
2021125
202268
202363
202475
202562
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Prohance Multipack (Gadoteridol) · HCPCS A9576

2024 spending

$407K

Beneficiaries

17,496

19,261 claims

Per beneficiary

$23

2024 ASP limit $1.49 per unit

View as table
YearSpending
2020$328,533
2021$373,358
2022$405,189
2023$435,799
2024$407,440

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.